TABLE 5

Comparison of pneumococcal OPA GMTs in subjects ≥65 years of age in the Mexican study versus the European Union comparator study in the evaluable immunogenicity populationsa

SerotypeOPA GMTs atb:
PrevaccinationPostvaccination
Mexican study (n = 146–161)EU study (n = 212–254)ComparisoncMexican study (n = 150–159)EU study (n = 234–255)Comparisonc
Ratio95% CIRatio95% CI
1761.20.95, 1.4784950.90.62, 1.26
31161.91.50, 2.4589511.81.29, 2.37
453143.72.18, 6.201,2091,4860.80.58, 1.15
51061.81.38, 2.362851122.61.68, 3.88
6A110176.43.99, 10.113,3431,5972.11.46, 2.99
6B388537.44.26, 12.733,3842,0171.71.17, 2.41
7F125913.58.53, 21.271,9298352.31.54, 3.47
9V173218.14.69, 14.161,4027231.91.22, 3.08
14361804.52.77, 7.381,3161,0881.20.86, 1.69
18C155226.94.21, 11.392,1971,4151.61.10, 2.20
19A105215.13.50, 7.511,1965392.21.60, 3.07
19F53153.62.33, 5.601,1884672.51.72, 3.76
23F2592.71.83, 4.019302953.11.98, 5.00
  • a OPA, opsonophagocytic activity; GMT, geometric mean titer.

  • b n values are the numbers of subjects with a valid and determinate OPA titer to the given serotype. The GMTs were calculated using all subjects with available data for the specified blood draw.

  • c The ratio of GMTs (Mexican study to EU study) was calculated by back transforming the mean difference between the studies on the logarithmic scale. The 95% confidence intervals (CIs) for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (Mexican study to EU study). The statistically significant differences are in bold type.